[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1962

Tinea Capitis Treated with Griseofulvin: Evaluation of Dosage Schedules and Some Immunological Studies

Author Affiliations


From the Therapeutic Evaluation Unit of the Division of Dermatology of the Department of Medicine at the State University of New York, Downstate Medical Center, 450 Clarkson Ave.

Arch Dermatol. 1962;85(6):743-745. doi:10.1001/archderm.1962.01590060053011

Since Gentles1 first reported the efficacy of griseofulvin in guinea pigs and Blank and Roth2 confirmed its usefulness in man, the value of this preparation as the first effective systemic agent for the dermatomycoses has been voluminously documented.3-9

We have studied 165 children with tinea capitis caused by Microsporum audouini, Microsporum lanosum, and Trichophyton tonsurans with various dosage schemes and have tried to correlate the trichophytin reaction to the response to griseofulvin in an effort to determine if immunological mechanisms play a role in this response.

A total of 207 children were treated, but only 165 were adequately followed, and these form the basis for this study. Of these 165 patients, 98 cases were caused by M. audouini and 4 patients had kerion. Eighty-eight were treated with griseofulvin in varying dosage; 10 were treated with 5% ammoniated mercury only as controls. Sixty-three cases were caused by M.